Citigroup Has Lowered Expectations for Clarivate (NYSE:CLVT) Stock Price

Clarivate (NYSE:CLVT) had its price objective reduced by equities research analysts at Citigroup from $2.80 to $2.50 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price target would indicate a potential upside of 25.31% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen raised shares of Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Stifel Nicolaus cut their price target on Clarivate from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a report on Wednesday, June 24th. The Goldman Sachs Group lowered their price objective on Clarivate from $2.90 to $2.60 and set a “neutral” rating for the company in a research note on Thursday. Finally, Barclays dropped their target price on Clarivate from $2.50 to $2.00 and set an “underweight” rating on the stock in a report on Thursday. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $3.02.

Clarivate Stock Down 7.2%

NYSE CLVT traded down $0.15 during mid-day trading on Thursday, hitting $2.00. The company’s stock had a trading volume of 4,179,151 shares, compared to its average volume of 6,810,947. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -9.55 and a beta of 1.38. The company’s 50 day simple moving average is $2.29 and its 200 day simple moving average is $2.43. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 0.89. Clarivate has a twelve month low of $1.66 and a twelve month high of $4.55.

Clarivate (NYSE:CLVT) last released its quarterly earnings data on Wednesday, July 29th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The firm had revenue of $587.30 million for the quarter, compared to the consensus estimate of $589.73 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The business’s revenue was down 5.5% on a year-over-year basis. Analysts anticipate that Clarivate will post 0.65 earnings per share for the current year.

Institutional Trading of Clarivate

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its holdings in Clarivate by 96.2% during the first quarter. Royal Bank of Canada now owns 63,630 shares of the company’s stock worth $250,000 after buying an additional 31,197 shares during the last quarter. AQR Capital Management LLC boosted its stake in Clarivate by 37.0% in the first quarter. AQR Capital Management LLC now owns 451,872 shares of the company’s stock valued at $1,749,000 after acquiring an additional 122,099 shares during the last quarter. Millennium Management LLC boosted its stake in Clarivate by 1,420.4% in the first quarter. Millennium Management LLC now owns 1,188,978 shares of the company’s stock valued at $4,673,000 after acquiring an additional 1,110,774 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Clarivate by 15.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 616,250 shares of the company’s stock valued at $2,422,000 after acquiring an additional 82,768 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Clarivate by 13.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,243,683 shares of the company’s stock worth $4,888,000 after purchasing an additional 144,462 shares during the last quarter. 85.72% of the stock is owned by hedge funds and other institutional investors.

Key Clarivate News

Here are the key news stories impacting Clarivate this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Clarivate reported second-quarter EPS of $0.19, above the $0.17-$0.18 analyst consensus and up from $0.18 a year earlier. Clarivate Reports Second Quarter 2026 Results
• Positive Sentiment: Management reaffirmed its 2026 financial outlook and said its Value Creation Plan is advancing strategic priorities, improving the company’s financial profile and supporting a sharper focus following the planned Life Sciences & Healthcare divestiture. Clarivate Reports Second Quarter 2026 Results
• Positive Sentiment: Stifel Nicolaus maintained a Buy rating and sees substantial potential upside, although it reduced its price target from $6 to $5. Clarivate Price Target Update
• Neutral Sentiment: Clarivate appointed Michael Easton as executive vice president and CFO, effective August 8. Easton, a longtime company executive with more than 25 years of financial and operational experience, will replace Jonathan Collins, who is leaving to pursue another opportunity. Clarivate Appoints Michael Easton as Chief Financial Officer
• Negative Sentiment: Revenue was weaker than expected and declined year over year. Quarterly revenue of $587.3 million missed the approximately $589.7 million consensus estimate and fell 5.5% from the prior-year period. Clarivate also reported a negative net margin, underscoring ongoing concerns about growth and profitability. Clarivate Q2 Earnings and Revenues
• Negative Sentiment: The lower Stifel price target signals reduced near-term expectations despite the continued Buy rating, adding pressure to the investment case.

Clarivate Company Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.